Shares of clinical-stage biopharma Paratek Pharmaceuticals (NASDAQ: PRTK) soared 37% today after news leaked that the company is considering a sale.The stock has returned solid gains to investors in the last year after a string of positive developments for its antibiotic pipeline, including positive phase 3 results for its top two drug candidates.